glp 1 npo guidelines GLP-1 RA guidance roundup π¨ Over 15 MILLION Americans
Description
This is an oral compound with a completely distinct mechanism from any GLP-1 receptor agonist.
Translational perspective for the use of dual GLP-1R/GcgR agonists for obesity Multiple clinical trials involving GLP-1R/GcgR co-agonists are currently underway (Table 1)
Peer review Peer review information Nature Aging thanks Ziyad Al-Aly, Yadong Huang and Olivier Rascol for their contribution to the peer review of this work
Bottom line: GLP-1 (semaglutide or tirzepatide) therapy can be highly valuable for older adults when used thoughtfully with attention to pre-existing conditions, individualized dose adjustments, and proactive risk mitigation strategies
Its role exhibits context-dependent duality, functioning as a cytoprotective mechanism or contributing to regulated cell death (Levine and Kroemer, 2019)
Yang YW, Hsieh TF, Li CI, Liu CS, Lin WY, Chiang JH, et al
